Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Total Liabilities
Apontis Pharma AG
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Total Liabilities
€27.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Total Liabilities
$50.5m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Total Liabilities
€78.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Merck KGaA
XETRA:MRK
|
Total Liabilities
€21.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Total Liabilities
€1.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Total Liabilities
€91.5m
|
CAGR 3-Years
90%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Total Liabilities?
Total Liabilities
27.2m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Total Liabilities amounts to 27.2m EUR.
What is Apontis Pharma AG's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
1%
Over the last year, the Total Liabilities growth was 49%. The average annual Total Liabilities growth rates for Apontis Pharma AG have been 1% over the past three years .
You don't have any saved screeners yet